EUVIMEDEUVIMED entdecken
Crossref

Emicizumab promotes factor Xa generation on endothelial cells

Ammon M Fager, Patrick Ellsworth, Nigel S Key, Dougald M Monroe, Maureane Hoffman

Journal of Thrombosis and Haemostasis · 2024

DOI: 10.1016/j.jtha.2024.02.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Ammon M Fager und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hematology/Oncology Service, Department of Veterans Affairs Medical Center, Durham, North Carolina, USA; Division of Hematology, Department of Medici…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Blood Coagulation Factors, Endothelial Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: BLRD VA, US Department of Veterans Affairs, Takeda Pharmaceuticals USA Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Until recently, the treatment of hemophilia A relied on factor (F)VIII replacement. However, up to one-third of patients with severe hemophilia A develop neutralizing alloantibodies that render replacement therapies ineffective. The development of emicizumab, a bispecific antibody that partially mimics FVIIIa, has revolutionized the treatment of these patients. However, the use of an activated prothrombin complex concentrate [FEIBA (Takeda)] to treat breakthrough bleeding in patients on emicizumab has been associated with thrombotic complications including a unique microangiopathy. OBJECTIVES: We hypothesized that the thrombotic complications observed with the combination of emicizumab and FEIBA might be due to excessive expression of procoagulant activity on the surface of endothelial cells. METHODS: We examined the ability of emicizumab to promote FX activation on endothelial cells using 2 cell culture models. RESULTS: We found that endothelial cells readily support emicizumab-mediated activation of FX by FIXa. The level of FXa generation depends on the concentration of available FIXa. The addition of FEIBA to emicizumab increased FXa generation in a dose-dependent manner on endothelial cells in both models. The rate of FXa generation was further enhanced by endothelial cell activation. However, unlike emicizumab, we found limited FXa generation in the presence of FVIII(a), which followed a significant lag time and was not dependent on FIXa concentration under these conditions. CONCLUSION: Emicizumab promotes FXa generation on the surface of endothelial cells, which is markedly enhanced in the presence of FEIBA. These findings demonstrate a potential mechanism for the thrombotic complications seen with the combined use of emicizumab and FEIBA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificAntibodies, Monoclonal, HumanizedBlood Coagulation FactorsEndothelial CellsFactor XaHumansBlood CoagulationCells, CulturedCoagulantsFactor IXHemophilia AHuman Umbilical Vein Endothelial Cells

Stichwörter der Autor:innen

coagulationemicizumabendotheliumfactor IXafactor VIIIahemophilia

Substanzen

anti-inhibitor coagulant complexAntibodies, BispecificAntibodies, Monoclonal, HumanizedBlood Coagulation FactorsCoagulantsemicizumabFactor IXFactor Xa

Autor:innen und Institutionen

  • Hematology/Oncology Service, Department of Veterans Affairs Medical Center, Durham, North Carolina, USA; Division of Hematology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA. E…
  • Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Department of…
  • Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Pathology and Laboratory Medicine Service, Department of Veterans Affairs Medical Center, Durham, North Carolina, USA; Department of Pathology, Duke University School of Medicine, Durham, North Carolina, USA.

Förderung

  • BLRD VA
  • US Department of Veterans Affairs
  • Takeda Pharmaceuticals USA Inc
  • Novo Nordisk A/S

Zitieren

APA

Fager, A. M., Ellsworth, P., Key, N. S., Monroe, D. M., & Hoffman, M. (2024). Emicizumab promotes factor Xa generation on endothelial cells. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.02.017

Vancouver

Fager AM, Ellsworth P, Key NS, Monroe DM, Hoffman M. Emicizumab promotes factor Xa generation on endothelial cells. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.02.017

BibTeX
@article{Fager2024,
  author = {Fager, Ammon M and Ellsworth, Patrick and Key, Nigel S and Monroe, Dougald M and Hoffman, Maureane},
  title = {Emicizumab promotes factor Xa generation on endothelial cells},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  doi = {10.1016/j.jtha.2024.02.017}
}
Kostenlos starten →